GLP1R and Hypoglycemia: While lowering HbA1c might be associated with an increase in the risk of hypoglycemia, Portugal has had a high uptake of innovative anti-hyperglycemic agents associated with lower risk of hypoglycemia (DPP4 inhibitors, SGLT2 inhibitors and GLP1 analogues) and a decrease in the use of sulphonylurea (SU) [3].